Melanie Leveridge

GlaxoSmithKline (GSK)

Trends in drug discovery from SLAS2020: From cellular target engagement technologies to AI disrupting pharmaceutical developments

Melanie Leveridge, SLAS2020 Co-Chair and Head of Screening, Profiling & Mechanistic Biology, GSK (UK), explores the hot drug discovery trends at SLAS2020, including artificial intelligence and cellular target engagement technologies for the progression of drug discovery projects. Leveridge also predicts the topics that will make an impact at SLAS2021, including omics technology and cell therapy.



LIKE 0
Melanie Leveridge
ELRIG SLAS2020 Drug discovery

Melanie Leveridge

Biography

Melanie is the head of the... More
Follow Melanie

Melanie Leveridge

GlaxoSmithKline (GSK)

Melanie is the head of the Screening Profiling and Mechanistic Biology department, at the GSK Medicines Research Centre in Stevenage, UK within the global NCE (New Chemical Entity) molecular discovery organization. She leads a department of 40 scientists to partner with therapy area units to select the best targets for small molecule approaches and build assays and mechanistic approaches to understand target:molecule interactions using a range of biochemical, biophysical, cellular and phenotypic assay approaches.